Your session is about to expire
← Back to Search
Iberdomide + Daratumumab + Carfilzomib + Dexamethasone for Multiple Myeloma (Iber-KDd Trial)
Iber-KDd Trial Summary
This trial will test a new combination of treatments for people with multiple myeloma that may be more effective than current treatments.
Iber-KDd Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowIber-KDd Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Iber-KDd Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have HIV, hepatitis B, or hepatitis C.I am using birth control and have had a recent negative pregnancy test.I have not had major surgery in the last 3 weeks.I am between 18 and 75 years old.I have high blood pressure in the lungs.My liver tests are within normal limits.I cannot take certain medications, including antivirals or blood thinners.I have multiple myeloma that got worse after or during my last treatment, and I've had 1-3 prior treatments including one with lenalidomide.I have previously been treated with carfilzomib under certain conditions.I have serious heart problems.I have an active hepatitis B or C infection.I do not have any serious illnesses or social situations that would stop me from following the study's requirements.My blood counts meet the required levels for the trial.I have been diagnosed with POEMS syndrome.I am currently on treatment for multiple myeloma, with some exceptions.My condition did not improve after treatment targeting CD38.I have been diagnosed with plasma cell leukemia.I have difficulty making decisions for myself.I can undergo treatments to prevent blood clots.My kidney function, measured by creatinine clearance, is good.I have previously received CD38-directed therapy under certain conditions.My lung function meets the required standards for someone with COPD.I have been diagnosed with amyloidosis.I have been active and mostly self-sufficient in the last month.My GI disease hasn't improved with standard treatments.I have COPD with less than half the normal lung function.My blood pressure or diabetes is not well-managed.I have severe nerve pain.I have been treated with iberdomide before.
- Group 1: Iber-KDd Combination Therapy
- Group 2: Iber Monotherapy
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is this clinical trial open to geriatric patients?
"The requirements outlined in the eligibility criteria for this trial necessitates that patients are no younger than 18 and no older than 75."
To what criteria do participants need to meet in order to join this research endeavor?
"Patients between 18 and 75 years old with a diagnosis of multiple myeloma are eligible to take part in this clinical trial. The research team is seeking up to 30 participants for the study."
Are any additional applicants being considered for this experiment?
"According to the information stored on clinicaltrials.gov, this trial is not actively accepting participants at present. This study was initially posted in August 1st of 2023 and the most recent update was May 31st of 2023. Although it is currently inactive, there are 822 other trials looking for patients right now."
What has been observed regarding the efficacy of Iber-KDd Combination Therapy?
"Iber-KDd Combination Therapy has been assigned a safety score of 2, as there is only some evidence that it does not pose a risk to users but no proof yet that it will be efficacious."
Share this study with friends
Copy Link
Messenger